BJC

## Differences in cancer awareness and beliefs between Australia, Canada, Denmark, Norway, Sweden and the UK (the International Cancer Benchmarking Partnership): do they contribute to differences in cancer survival?

L J L Forbes, A E Simon, F Warburton, D Boniface, K E Brain, A Dessaix, C Donnelly, K Haynes, L Hvidberg, M Lagerlund, G Lockwood, C Tishelman, P Vedsted, M N Vigmostad, A J Ramirez, J Wardle and the International Cancer Benchmarking Partnership Module 2 Working Group

Correction to: British Journal of Cancer (2013) 108, 292-300. doi:10.1038/ bjc.2012.542

Upon publication of this paper in Volume 108, the authors recognised a calculation error in the row 'estimated response rate' of Table 1. The corrected Table 1 is now presented below.

Table 1. Response rates									
	Australia	Canada	Denmark	Norway	Sweden	UK			
Total number of households with connected telephone numbers approached	35730	46 672	5369	8921	7411	80210			
Number of households of unknown eligibility <sup>a</sup>	20719	34 828	899	1922	1901	55 979			
Number of households of known eligibility	15011	11 844	4470	6999	5510	24231			
Number of households in which the individual declined to take part either during or after assessment of eligibility		1195	2337	4726	3345	3468			
Number of ineligible households <sup>a</sup>		8571	12	24	19	13 234			
Number of eligible households <sup>a</sup>		3273	4458	6975	5491	10 997			
Proportion of households eligible among those assessed for eligibility (%)		27.6	99.7	99.7	99.7	45.4			
Completed interviews		2064	2000	2009	2039	6965			
Minimum response rate (%) <sup>b</sup>	15.9	5.4	31.5	23.2	28.0	10.5			
Estimated response rate (%) <sup>c</sup>	35.8	16.0	38.2	23.2	28.0	19.4			

<sup>a</sup>A household was eligible if one or more people aged 50+ lived in the household.

<sup>b</sup>The minimum response rate represents the represents the response rate assuming all households that we could not assess for eligibility were eligible, in other words the lowest possible response rate. It is calculated as the number of complete interviews divided by the number of interviews plus the number of incomplete interviews among eligible people (refusals and break-offs plus non-contacts) plus the number of all households of unknown eligibility (equivalent to the American Association for Public Opinion Research response rate formula 1).

<sup>c</sup>The estimated response rate represents the response rate after adjusting the size of the denominator for the likely proportion of households that were eligible. It is calculated by assuming that the proportion eligible among households of unknown eligibility is the same as the proportion of those tested for eligibility who were eligible (equivalent to American Association for Public Opinion Research response rate formula 3).

## BJC

British Journal of Cancer (2014) 111, 2382 | doi:10.1038/bjc.2014.550

## Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer

W Koizumi, K Yamaguchi, H Hosaka, Y Takinishi, N Nakayama, T Hara, K Muro, H Baba, Y Sasaki, T Nishina, N Fuse, T Esaki, M Takagi, M Gotoh and T Sasaki

Correction to: British Journal of Cancer (2013) 109, 2079–2086. doi: 10.1038/ bjc.2013.555

Upon publication of this paper in Volume 109, the authors recognised some errors relating to the units in Table 3. The corrected Table 3 is now presented below.

			PKparameters			
	Group	No. of patients	t <sub>max</sub> (h)	$C_{\rm max}$ ( $\mu g  { m ml}^{-1}$ )	$AUC_{0-last}$ ( $\mu g h^{-1} m l^{-1}$ )	t <sub>1/2</sub> (h)
TSU-68	A	6	3.5 ± 1.5	4.46 ± 0.95	23.2±7.0	$2.2 \pm 0.7$
	Group	No. of patients	t <sub>max</sub> (h)	C <sub>max</sub> (ng ml <sup>-1</sup> )	$AUC_{0-last} (ng h^{-1} ml^{-1})$	t <sub>1/2</sub> (h)
S-1						
FT	A	12	2.3±0.8	2168 ± 378** 13 368 ± 2581**		6.9±1.1**
	В	12	$2.4 \pm 1.2$	3693 ± 1309	29 219 ± 10 288	$13.3 \pm 4.4$
5-FU	A	12	3.1±0.7	202 ± 65	891±315	1.6±0.3**
	В	12	3.8±1.2	160 ± 37	976 ± 221	$2.4 \pm 0.6$
CDHP	A	12	2.6±0.8	228 ± 55	993±229**	2.9±0.6*
	В	12	2.7 ± 1.1	263 ± 94	1442 ± 337	$3.8 \pm 0.8$
Охо	A	12	3.3±1.8	44 ± 22*	258±133*	3.2±0.9
	В	12	3.0±1.7	90 ± 59	498 ± 285	4.6±2.3
CDDP						
Free platinum	A	6	1.7 ± 0.5	1277 ± 169*	2813±360*	0.783 ± 0.071
	В	7	$2.0 \pm 0.0$	$1585 \pm 284$	3441 ± 437	$0.819 \pm 0.070$

Abbreviations: CDHP = 5-chloro-2,4-dihydroxypyridine; FT = 5-fluoro-1-(tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione (tegafur); 5-FU = 5-fluorouracil; Oxo = monopotassium 1,2,3,4-tetrahydro-2,4-dioxo-1,3,5-triazine-6-carboxylate (oxonic acid). Mean ± s.d. \*P-value < 0.05; \*\*P-value < 0.001.

© 2014 Cancer Research UK. All rights reserved 0007 – 0920/14